What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Osteoporosis
- Endocrinology
Osteoporosis, Endocrinology, Internal medicine, Parathyroid hormone and Bone density are her primary areas of study.
Her Osteoporosis research is multidisciplinary, relying on both Surgery and Urology.
Felicia Cosman combines subjects such as Hip fracture and Denosumab with her study of Surgery.
In her research on the topic of Endocrinology, Calcitonin, Oral administration, Estrogen and Nasal administration is strongly related with Calcium.
Her Internal medicine study which covers Skeleton that intersects with Bone tissue and Menopause.
Her Parathyroid hormone study incorporates themes from Cortical bone, Iliac crest, Anabolism, Biopsy and Resorption.
Her most cited work include:
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (2156 citations)
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (1945 citations)
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (1412 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Osteoporosis, Internal medicine, Endocrinology, Bone mineral and Bone density.
The various areas that Felicia Cosman examines in her Osteoporosis study include Placebo, Surgery and Urology.
Her study in Bone remodeling, Parathyroid hormone, Bone resorption, Abaloparatide and Estrogen falls within the category of Internal medicine.
Her research investigates the connection between Endocrinology and topics such as Calcium metabolism that intersect with issues in Urinary calcium.
Her studies in Bone mineral integrate themes in fields like Randomized controlled trial and Tibia.
Her studies deal with areas such as Physical therapy, Nuclear medicine and Anatomy as well as Bone density.
She most often published in these fields:
- Osteoporosis (69.86%)
- Internal medicine (66.67%)
- Endocrinology (51.60%)
What were the highlights of her more recent work (between 2016-2021)?
- Osteoporosis (69.86%)
- Internal medicine (66.67%)
- Abaloparatide (13.70%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Osteoporosis, Internal medicine, Abaloparatide, Placebo and Teriparatide.
Her Osteoporosis research is multidisciplinary, incorporating elements of Postmenopausal women, Incidence and Urology.
Much of her study explores Internal medicine relationship to Endocrinology.
Her Abaloparatide research entails a greater understanding of Parathyroid hormone.
Her Placebo research incorporates elements of Relative risk reduction and Surgery.
Her Teriparatide research incorporates themes from Cancellous bone, Anabolism, Anabolic Agents, Bone density and Denosumab.
Between 2016 and 2021, her most popular works were:
- The 2017 hormone therapy position statement of The North American Menopause Society. (467 citations)
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. (96 citations)
- Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis (72 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Osteoporosis
- Surgery
Her primary areas of investigation include Osteoporosis, Internal medicine, Placebo, Bone mineral and Abaloparatide.
She has researched Osteoporosis in several fields, including Physical therapy and Treatment goals.
Her Internal medicine research is mostly focused on the topic Femoral neck.
Her research in Bone mineral focuses on subjects like Incidence, which are connected to Clinical trial and Risk factor.
Her Abaloparatide course of study focuses on Randomized controlled trial and Endocrinology.
Her biological study spans a wide range of topics, including Teriparatide and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
